Soleno Therapeutics (SLNO) Operating Expenses (2016 - 2017)
Historic Operating Expenses for Soleno Therapeutics (SLNO) over the last 5 years, with Q4 2017 value amounting to $5.2 million.
- Soleno Therapeutics' Operating Expenses rose 18361.53% to $5.2 million in Q4 2017 from the same period last year, while for Sep 2018 it was $5.2 million, marking a year-over-year decrease of 4095.48%. This contributed to the annual value of $187.7 million for FY2024, which is 35348.69% up from last year.
- According to the latest figures from Q4 2017, Soleno Therapeutics' Operating Expenses is $5.2 million, which was up 18361.53% from $2.6 million recorded in Q3 2017.
- Soleno Therapeutics' 5-year Operating Expenses high stood at $5.2 million for Q4 2017, and its period low was $559783.0 during Q4 2013.
- For the 5-year period, Soleno Therapeutics' Operating Expenses averaged around $2.3 million, with its median value being $2.1 million (2016).
- As far as peak fluctuations go, Soleno Therapeutics' Operating Expenses skyrocketed by 25526.32% in 2015, and later tumbled by 6768.65% in 2017.
- Over the past 5 years, Soleno Therapeutics' Operating Expenses (Quarter) stood at $559783.0 in 2013, then soared by 229.72% to $1.8 million in 2014, then surged by 89.17% to $3.5 million in 2015, then plummeted by 47.5% to $1.8 million in 2016, then skyrocketed by 183.62% to $5.2 million in 2017.
- Its Operating Expenses stands at $5.2 million for Q4 2017, versus $2.6 million for Q3 2017 and $3.0 million for Q2 2017.